

Applicant: Yuan et al.
 Serial No.: 09/848,159
 Filed: May 3, 2001
 Page 2 of 7

Sub P2
 25. (Amended) A method for treating hyperlipidemia in a mammal, said method comprises a step of administering to said mammal an effective amount of 4-[[4-(4-ethylphenyl)-2,2-dimethyl-(2H)-thiochromen-6-yl]-ethynyl]-benzoic acid.

A2
Sub C1 Cont
 26. (Amended) A method of claim 24 wherein the step of administering 4-[[4-(4-ethylphenyl)-2,2-dimethyl-(2H)-thiochromen-6-yl]-ethynyl]-benzoic acid lowers the level of circulating triglycerides.

Support for the Amendments:

Support for the amendment to claim 5 may be found at least at page 25, lines 17-20. Applicant has amended claim 5 as suggested by the Examiner. Claim 5 now recites that the RAR antagonist or inverse agonist acts as a prophylaxis for myocardial infarction. In other words, the compounds recited in claim 5 are a prevention for myocardial infarction.

The amendments to the claims 25 and 26 are formal in nature. No new matter has been added.

The amendments to the claims have been made to more clearly claim and present the present invention. The amendments to the claims are not made for a reason related to the statutory requirements of patentability and/or the claims as a whole have not been narrowed. Hence, the amended claims are not subject to the rule set forth in *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.*, 56 USPQ2d 1865 (Fed. Cir. 2000).

Remarks

By way of this Response, claims 5, 25, and 26 have been amended. Claims 1-26 are pending.